MTOR Inhibitors

03/01/2011 - "The published data on new mTOR inhibitors are still limited, but the available preclinical results indicate that they have a potent antiproliferative activity against a broad panel of tumor cell lines, have a favorable safety profile, can obtain disease stabilization or even tumor regression and, in some cases, enhance the efficacy of other targeted or standard-of-care anticancer drugs when used in vivo in preclinical studies."
10/24/2012 - "More recently mTOR inhibitors proven to be effective in the treatment of some cancers also in general population. "
11/01/2017 - "In this series, mTOR inhibitors were not only safe and well tolerated, but also beneficial for tumor resection."
06/28/2016 - "Although mTOR inhibitors have significantly improved survival of different cancer patients, resistance and lack of predictive factors of response remain unsolved issues. "
01/01/2016 - "Animal studies have provided evidence that mTOR inhibitors improved tumor-specific T-cells adoptive transfer in which the quality of CD8+ T-cells is a major factor for predicting success. "

08/01/2014 - "The mTOR inhibitors have improved outcomes for patients with metastatic renal cell carcinoma (mRCC) but the duration of benefit is variable. "
03/01/2014 - "Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature."
10/01/2011 - "Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors."
11/01/2023 - "CircPTEN suppresses human clear cell renal carcinoma progression and resistance to mTOR inhibitors by targeting epigenetic modification."
09/01/2022 - "PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma."

01/01/2015 - "We have addressed the question of whether mTOR inhibitors may be more effective in combination than singly in inhibiting the proliferation of breast cancer cells. "
01/01/2018 - "ET + CDK4/6 or mTOR inhibitors are likely safe and effective in older patients with HR+, HER2- advanced breast cancer."
04/01/2009 - "mTOR inhibitors seemed to be potentially useful for the treatment of breast cancer with acceptable safety profile. "
08/01/2016 - "The aim of this paper is to focus on the safety and efficacy of mTOR inhibitors in the treatment of breast cancer. "
01/01/2016 - "Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors."

01/01/2023 - "Further explorations are needed to evaluate the therapeutic efficacy and application value of mTOR inhibitors in epilepsy. "
01/01/2015 - "Recently, mTOR inhibitors have also been reported to be a potential anti-epileptic drug, which may be effective when used in young patients with genetic epilepsy. "
06/01/2013 - "Future clinical and basic research is needed to establish whether mTOR inhibitors are an effective treatment for epilepsy."
05/01/2019 - "Meanwhile, epilepsy models with aberrant activation of the mTOR pathway have helped elucidate the role of the mTOR pathway in epileptogenesis, and evidence from epilepsy models of human mutations recapitulating the features of epileptic patients has indicated that mTOR inhibitors may be of use in treating epilepsy associated with mutations in mTOR pathway genes. "
06/01/2023 - "Despite frequent use of mTOR inhibitors, there are only a few studies on their effect on epilepsy control in children under 2 years of age. "

06/01/2012 - "The role of mTOR inhibitors in the management of angiomyolipomas needs to be defined. "
11/01/2013 - "Targeted therapies, such as mTOR inhibitors, which have demonstrated efficacy in maintaining and reducing renal angiomyolipoma size, are of great benefit to patients. "
10/01/2018 - "There are several cases of malignant angiomyolipoma which exhibit transient responses to mTOR inhibitors, forming the basis of current practice guidelines in malignant PEComa. "
01/01/2016 - "We also review recent advances in the medical treatment of patients with tuberous sclerosis complex associated angiomyolipomas with mTOR inhibitors. "
06/01/2017 - "Recently, the employment of mTOR inhibitors such as Everolimus has been shown therapeutic efficacy in this disease, especially in terms of a dimensional reduction of renal angiomyolipomas."